Pentoxifylline Shows Promise for Diabetic Kidney Disease
A new meta-analysis finds the drug reduces albuminuria, though more evidence is needed to confirm its impact on kidney failure.
Updated on Oct. 23, 2026 in Diabetes
Live Poll
Should medical researchers prioritize repurposing older, inexpensive generic drugs to treat chronic kidney disease?
Researchers presented a systematic review at ASN Kidney Week 2026 showing that pentoxifylline reduces albuminuria and improves GFR in patients with diabetic kidney disease. However, evidence remains limited regarding its ability to prevent kidney failure or death.
Why it matters
The analysis addresses gaps in previous research by incorporating modern prediction intervals and assessing trial evidence accrual. This work is critical as most prior studies predated the widespread adoption of SGLT2 inhibitors and GLP-1 receptor agonists.
The meta-analysis of 34 studies found that while pentoxifylline increased GFR by a mean of 4.49 mL/min/1.73 m², it also tripled the risk of gastrointestinal adverse events. Serious adverse events did not show a statistically significant increase.
The players
ASN Kidney Week 2026
This is a major annual scientific meeting for nephrology professionals hosted by the American Society of Nephrology.
VA PTXRx trial
This is a large-scale, pragmatic, randomized, placebo-controlled clinical trial currently investigating the impact of pentoxifylline on kidney health.
The details
Investigators performed a systematic review, meta-analysis, and trial sequential analysis of 34 studies to evaluate the efficacy of oral pentoxifylline. The current VA PTXRx trial, featuring 2,376 participants, is ongoing to provide more definitive data on clinical outcomes.
Timeline
Trials conducted before 2019 lacked the modern standard medications used today.
The database search for randomized trials concluded in June 2026.
The findings were presented at ASN Kidney Week 2026 from October 21-25, 2026.
The VA PTXRx trial is expected to report results in 2027.
Health Landscape
This meta-analysis provides a critical interim evaluation while the medical community awaits the final, definitive results from the VA PTXRx trial. It highlights the challenge of assessing older pharmacological interventions in the era of modern SGLT2 inhibitors and GLP-1 receptor agonists.
Patients may experience a higher incidence of gastrointestinal side effects if prescribed pentoxifylline, as the risk is three times higher than with a placebo. Clinicians and patients should discuss these potential side effects while awaiting more robust data from the ongoing VA PTXRx trial.
The takeaway
While pentoxifylline shows promise in improving specific kidney biomarkers, the lack of sufficient data on major clinical outcomes means it is not yet a definitive treatment for preventing failure. Patients should consult with their nephrologists to weigh these findings against established standards of care.
What happens next
The VA PTXRx trial, which involves 2,376 patients, is expected to release its findings in 2027, potentially offering more conclusive evidence regarding the drug's effect on kidney failure and patient mortality.
Further reading
Learn more about the latest research and management strategies in our Diabetes section.
Source note: This article includes information reported by Hcplive.
Live Poll
Should medical researchers prioritize repurposing older, inexpensive generic drugs to treat chronic kidney disease?
